Assertio Holdings, Inc. has entered into a merger agreement on April 8, 2026, to be acquired by Garda Therapeutics, offering $18.00 cash per share plus potential earn-outs. This significant event, categorized under Acquisitions and mergers, reflects a positive sentiment for investors as the Company moves towards becoming a wholly-owned subsidiary.